Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulf Peters

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Journal of the American Chemical Society|November 1, 2013
Staurosporine-derived inhibitors broaden the scope of analog-sensitive kinase technologyMichael S Lopez, Jonathan W Choy, Ulf Peters, et al.
Nature Structural & Molecular Biology|May 16, 2018
The reactivity-driven biochemical mechanism of covalent KRAS<sup>G12C</sup> inhibitorsRasmus Hansen, Ulf Peters, Anjali Babbar, et al.
Cancer Discovery|January 8, 2016
Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive StateMatthew P Patricelli, Matthew R Janes, Lian-Sheng Li, et al.
Cell|January 27, 2018
Targeting KRAS Mutant Cancers with a Covalent G12C-Specific InhibitorMatthew R Janes, Jingchuan Zhang, Lian-Sheng Li, et al.
Journal of Medicinal Chemistry|April 1, 2026
Optimization of Covalent 6-Cyanoquinazoline KRAS<sup>G12C</sup> Inhibitors for the Treatment of Solid TumorsJesse P Waldo, Paul J Krawczuk, Christopher B Kelly, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Journal of the American Chemical Society|November 1, 2013
Staurosporine-derived inhibitors broaden the scope of analog-sensitive kinase technologyMichael S Lopez, Jonathan W Choy, Ulf Peters, et al.
Nature Structural & Molecular Biology|May 16, 2018
The reactivity-driven biochemical mechanism of covalent KRAS<sup>G12C</sup> inhibitorsRasmus Hansen, Ulf Peters, Anjali Babbar, et al.
Cancer Discovery|January 8, 2016
Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive StateMatthew P Patricelli, Matthew R Janes, Lian-Sheng Li, et al.
Cell|January 27, 2018
Targeting KRAS Mutant Cancers with a Covalent G12C-Specific InhibitorMatthew R Janes, Jingchuan Zhang, Lian-Sheng Li, et al.
Journal of Medicinal Chemistry|April 1, 2026
Optimization of Covalent 6-Cyanoquinazoline KRAS<sup>G12C</sup> Inhibitors for the Treatment of Solid TumorsJesse P Waldo, Paul J Krawczuk, Christopher B Kelly, et al.
Pageof 2